Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxymethamphetamine Disposition in Humans: Use of Paroxetine as a Metabolic Inhibitor Probe

Author： Segura Mireia   Farré Magí   Pichini Simona  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.44, Iss.6, 2005-01, pp. : 649-660

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sex Differences in 3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy)-Induced Cytochrome P450 2D6 Inhibition in Humans

By Yubero-Lahoz Samanta   Pardo Ricardo   Farré Magí   O'Mahony Brian   Torrens Marta   Mustata Cristina   Pérez-Mañá Clara   Carbó Marcel·lí   >  

Clinical Pharmacokinetics, Vol. 50, Iss. 5, 2011-05 ,pp. : 319-329

Adis International

Access to resources Recommend Favorite

Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy

By Ververs F.F. Tessa  

Clinical Pharmacokinetics, Vol. 48, Iss. 10, 2009-10 ,pp. : 677-683

Adis International

Access to resources Recommend Favorite

Paroxetine metabolism is affected by cytochrome P450 (CYP) 2D6 polymorphism

By  

Inpharma, Vol. 1, Iss. 1468, 2004-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Bupropion [amfebutamone] sustained-release (SR) is a potent inhibitor of cytochrome P450 (CYP)2D6

By  

Reactions Weekly, Vol. 1, Iss. 1063, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D

By Delaforge M.   Jaouen M.   Bouille G.  

Environmental Toxicology and Pharmacology, Vol. 7, Iss. 3, 1999-07 ,pp. : 153-158

Elsevier

Access to resources Recommend Favorite